Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Role of genetic mutations in metabolic genes in sensorimotor neuropathies

FY 2020-21

Summary
We have identified a new mutation in HADHB from a patient at the Montreal Neurological Institute (MNI) leading to a rare sensorimotor neuropathy resembling an axonal Charcot-Marie-Tooth (CMT) disease. The pathophysiology behind how these mutations result in such peripheral neuropathy are poorly understood, but the patient has elevated acylcarnitine in blood. New studies have found long chain acylcarnitine accumulation causing axonal degeneration. Preliminary data collected in Dr Gentil's laboratory showing changes in cellular and mitochondrial viability in fibroblasts when treated with C-18 acylcarnitine have led us to explore new pathophysiological pathways for this motor disease. We hypothesize that the acylcarnitine accumulation is causing the neuropathic phenotype observed in the patient. Our objectives are to determine the effect of C-18 acylcarnitine in cellular viability and mitochondrial morphology in patient derived fibroblasts, to generate neuronal and myocyte models of the patient's pathology using CRISPR-induced HADHB knockouts and to explore potential gene therapies to manage the patient's condition or restore his peripheral motricity. Techniques such as CRISPR genome editing, immunofluorescence and MTT testing will be used to assess protein distribution and viability in patient-derived fibroblasts when treated with C-18 acylcarnitine. Furthermore, HADHB knockout models of motor neurons and muscle cells will be generated, representing an in-vitro model of the pathology. All lab work will be performed in Dr Gentil Laboratory at the MNI This work will serve to better understand the pathophysiology behind this motor disease and act as the preliminary work to find therapies that may help patients affected by sensorimotor neuropathies due to HADHB mutations.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
449652
Name
Dagher Robin
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Role of genetic mutations in metabolic genes in sensorimotor neuropathies
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acylcarnitine; Fatty Acid Metabolism; Genetic Disease; Human Fibroblasts; Mitochondrial Activity; Myocyte Viability; Neuron Viability; Peripheral Neuropathy; Rare Neurological Disease; Schwann Cell Metabolism
Abstract
We have identified a new mutation in HADHB from a patient at the Montreal Neurological Institute (MNI) leading to a rare sensorimotor neuropathy resembling an axonal Charcot-Marie-Tooth (CMT) disease. The pathophysiology behind how these mutations result in such peripheral neuropathy are poorly understood, but the patient has elevated acylcarnitine in blood. New studies have found long chain acylcarnitine accumulation causing axonal degeneration. Preliminary data collected in Dr Gentil's laboratory showing changes in cellular and mitochondrial viability in fibroblasts when treated with C-18 acylcarnitine have led us to explore new pathophysiological pathways for this motor disease. We hypothesize that the acylcarnitine accumulation is causing the neuropathic phenotype observed in the patient. Our objectives are to determine the effect of C-18 acylcarnitine in cellular viability and mitochondrial morphology in patient derived fibroblasts, to generate neuronal and myocyte models of the patient's pathology using CRISPR-induced HADHB knockouts and to explore potential gene therapies to manage the patient's condition or restore his peripheral motricity. Techniques such as CRISPR genome editing, immunofluorescence and MTT testing will be used to assess protein distribution and viability in patient-derived fibroblasts when treated with C-18 acylcarnitine. Furthermore, HADHB knockout models of motor neurons and muscle cells will be generated, representing an in-vitro model of the pathology. All lab work will be performed in Dr Gentil Laboratory at the MNI This work will serve to better understand the pathophysiology behind this motor disease and act as the preliminary work to find therapies that may help patients affected by sensorimotor neuropathies due to HADHB mutations.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Dagher, Robin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~